Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer - Trial NCT06259058
Access comprehensive clinical trial information for NCT06259058 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Tianjin Medical University Cancer Institute and Hospital and is currently Not yet recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 96 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tianjin Medical University Cancer Institute and Hospital
Timeline & Enrollment
Phase 1/2
Apr 01, 2024
Dec 01, 2027
Primary Outcome
R0 resection rate
Summary
This multicentric open-label trial will compare the efficacy and safety of stereotactic body
 radiation therapy (SBRT) followed by NALIRIFOX (5-fluorouracil, leucovorin, irinotecan
 liposome injection and oxaliplatin) vs NALIRIFOX for borderline resectable pancreatic cancer
 (BRPC).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06259058
Non-Device Trial